The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Asciminib is a potent, orally bioavailable, investigational drug that specifically and potently
inhibits the tyrosine kinase activity of native ABL1, together with that of the chimeric BCR …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation, and survival. Overexpression and overactivation of …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved
due to advances in drug development and rational treatment intervention strategies. Despite …

Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …

Prognostic scores support clinicians in selecting risk-adjusted treatments and in
comparatively assessing different results. For patients with chronic-phase chronic myeloid …

Evidence-based recommendations have been established for treatment of chronic myeloid
leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …